TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18272892

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Paclitaxel in contrast medium
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (uncoated balloons without paclitaxel)
Number of subjects: 154
Study: 16379563

Group type: EXPERIMENTAL
Intervention: Flax fiber supplement (15 g/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Psyllium supplement (10.4 g/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Flax bread
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control white bread
Number of subjects: 26
Study: 12784171

Group type: EXPERIMENTAL
Intervention: Incremental exercise to determine maximal aerobic velocity (MAV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Constant load exercise at 90% MAV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Constant load exercise at 100% MAV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test-retest perceived exertion ratings
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heart rate (HR) values
Number of subjects: 30
Study: 10561205

Group type: EXPERIMENTAL
Intervention: Chemotherapy with tamoxifen
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Chemotherapy without tamoxifen
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without tamoxifen
Number of subjects: 2016
Study: 8736587

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1301365

Group type: EXPERIMENTAL
Intervention: Head reorientation 2 seconds after cessation of head rotation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Postrotatory nystagmus (PRN)
Number of subjects: 10
Study: 3889258

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31022110

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 12278
Study: 30372830

Group type: EXPERIMENTAL
Intervention: MgSO4 (50 mg/kg infused intravenously within 15 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (same volume as MgSO4)
Number of subjects: 60
Study: 25128211

Group type: COMPARATOR
Intervention: Teacher-led intervention
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: RHS-led intervention
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Gardening score improvement by 3 levels (irrespective of group allocation)
Number of subjects: 641
Study: 22336878

Group type: EXPERIMENTAL
Intervention: TUTI‐16 vaccine (30 μg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TUTI‐16 vaccine (1 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TUTI‐16 vaccine
Number of subjects: 0
Study: 19703327

Group type: EXPERIMENTAL
Intervention: DHA (220 mg/d)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: DHA+AA (220 mg each/d)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control
Number of subjects: 119
Study: 17589194

Group type: EXPERIMENTAL
Intervention: MDOT
Number of subjects: 87

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 87
Study: 15760635

Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation (rTMS) over the left motor cortex (MC)
Number of subjects: 7
Study: 12377399

Group type: EXPERIMENTAL
Intervention: Theophylline (0.66 mg/kg, maximum dose of 500 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Schizophrenia group (baseline results from 17 drug-treated patients)
Number of subjects: 13
Study: 10463785

Group type: EXPERIMENTAL
Intervention: Oral glucose (1 ml 30% glucose) prior to skin puncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heel stick without oral glucose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Venepuncture without oral glucose
Number of subjects: 120
Study: 8157401

Group type: EXPERIMENTAL
Intervention: Softened fabrics (washed with liquid fabric softener)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unsoftened fabrics (washed with granular detergent)
Number of subjects: 24
Study: 2688080

Group type: EXPERIMENTAL
Intervention: Tenoxicam suppositories (20 mg once daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Piroxicam suppositories (20 mg once daily)
Number of subjects: 48
Study: 31926605

Group type: EXPERIMENTAL
Intervention: Intravenous siponimod (0.25 mg/3 h)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous siponimod (1 mg/24 h)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral siponimod (0.25 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous siponimod (0.25 mg/3 h) and Oral siponimod (0.25 mg)
Number of subjects: 33
Study: 29480043

Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 153
Study: 28450218

Group type: EXPERIMENTAL
Intervention: Provider-delivered patient financial incentive ($50 for completing online ACP tool and a lottery for discussing ACP)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Mail-delivered patient financial incentive
Number of subjects: 367
Study: 25475516

Group type: EXPERIMENTAL
Intervention: Ghost ileostomy (GI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No protective stoma (Control group B)
Number of subjects: 55
Study: 23279198

Group type: EXPERIMENTAL
Intervention: 5Hz rTMS over contra-lesional pharyngeal motor cortex for 10 min per day for 2 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation under the same condition
Number of subjects: 18
Study: 21649852

Group type: EXPERIMENTAL
Intervention: 1-day brief intervention smoking cessation training
Number of subjects: 57
Study: 18088400

Group type: EXPERIMENTAL
Intervention: MegaCHOP for three courses followed by BEAM and ASCT
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: IFE followed by BEAM and ASCT
Number of subjects: 86

Group type: COMPARATOR
Intervention: MegaCHOP and BEAM/ASCT
Number of subjects: 86
Study: 16931680

Group type: EXPERIMENTAL
Intervention: Hypercapnia (end‐tidal Pco2 50 mm Hg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normocapnia (end‐tidal Pco2 35 mm Hg)
Number of subjects: 30
Study: 12544376

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11130251

Group type: EXPERIMENTAL
Intervention: IV granisetron (G) 3 mg once a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV tropisetron (T) 5 mg once a day
Number of subjects: 45

Group type: COMPARATOR
Intervention: IV ondansetron (O) 8 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV granisetron (G)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV tropisetron (T)
Number of subjects: 45

Group type: COMPARATOR
Intervention: IV ondansetron (O)
Number of subjects: 45
Study: 8847874

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Simvastatin (20 mg/day)
Number of subjects: 133
Study: 8227493

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment in OCD patients with chronic tic disorder
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fluvoxamine treatment in OCD patients without chronic tic disorder
Number of subjects: 66
Study: 2941372

Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic peptide 0.5 micrograms/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic peptide 5.0 micrograms/min
Number of subjects: 8
Study: 30280640

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral-valve repair plus medical therapy (device group)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 614
Study: 25643617

Group type: EXPERIMENTAL
Intervention: Low-intensity strength training with vascular occlusion (LI-BFR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-intensity strength training (HI)
Number of subjects: 0
Study: 24729507

Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g
Number of subjects: 2060

Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 7 days
Number of subjects: 2060
Study: 22107338

Group type: EXPERIMENTAL
Intervention: Genetic causes (for heart disease risk)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Genetic causes (for depression)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Environmental, family history, family history & genetic test (for heart disease risk)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Severity (higher or low)
Number of subjects: 647
Study: 19584736

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18167160

Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed formula (eHF)
Number of subjects: 77

Group type: COMPARATOR
Intervention: amino acid formula (AAF)
Number of subjects: 77
Study: 15633707

Group type: EXPERIMENTAL
Intervention: Dichotic-aiming task using selective dichotic-listening procedure
Number of subjects: 52
Study: 12449847

Group type: EXPERIMENTAL
Intervention: Slow waves and sharp waves (spikes)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Seizure-free patients
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: EEG groups with slow and sharp waves
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: First EEG record findings
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: More slow waves and sharp waves
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Minimal slowing and rare discharges
Number of subjects: 255
Study: 10351967

Group type: EXPERIMENTAL
Intervention: Attenuation/scatter corrected images
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Attenuation/scatter corrected data with quantitative analysis
Number of subjects: 184

Group type: COMPARATOR
Intervention: Uncorrected perfusion data
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Attenuation/scatter correction
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Attenuation/scatter correction methodology
Number of subjects: 184
Study: 7580297

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: LPS (20 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Solvent solution
Number of subjects: 7
Study: 1935285

Group type: EXPERIMENTAL
Intervention: Hand-held nebulizer (HHN) with metaproterenol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Metered dose inhaler (MDI) via spacer (InspirEase)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hand-held nebulizer (HHN) with metaproterenol in asthmatic patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hand-held nebulizer (HHN) with metaproterenol in COPD patients
Number of subjects: 17
Study: 7025874

Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 0
Study: 30852363

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 119
Study: 28494906

Group type: COMPARATOR
Intervention: Bupivacaine group (GB): 20ml 0.5% bupivacaine diluted in 20ml saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine group (GM): 20ml 0.5% bupivacaine + 10mg morphine sulphate diluted in 20ml saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine group (GM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine group (GB)
Number of subjects: 60
Study: 26920896

Group type: EXPERIMENTAL
Intervention: Zedoary herbal tea (ZHT) T1 (500 mg ZRDP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zedoary herbal tea (ZHT) T2 (1 g ZRDP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zedoary herbal tea (ZHT) T3 (1.5 g ZRDP)
Number of subjects: 30
Study: 24336837

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (25 sessions over 13 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular soccer training (Control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise
Number of subjects: 0
Study: 21698213

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 19554666

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced whole-heart MRA at 3.0 T using gadofosveset
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncontrast-enhanced SSFP coronary MRA at 1.5 T
Number of subjects: 20
Study: 17605568

Group type: EXPERIMENTAL
Intervention: Condom promotion videotape (male presenter)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Condom promotion videotape (female presenter)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 220
Study: 15322643

Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled and deionized water
Number of subjects: 20
Study: 11680070

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 4
Study: 9012720

Group type: EXPERIMENTAL
Intervention: Mammography arm
Number of subjects: 3

Group type: COMPARATOR
Intervention: Usual-care arm
Number of subjects: 3
Study: 7699642

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1.5 g/kg every 2 weeks for 2 months, then monthly for 4 months (total: up to 9 infusions over 6 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) and Placebo
Number of subjects: 31
Study: 3322590

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (10 mg/m2) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxorubicin (50-60 mg) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (CNF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxorubicin (CAF)
Number of subjects: 60
Study: 30069614

Group type: EXPERIMENTAL
Intervention: Online HIV prevention program (Keep It Up! 2.0)
Number of subjects: 2984

Group type: COMPARATOR
Intervention: Recruitment from various venues (community-based organizations, Facebook, dating apps, outreach events)
Number of subjects: 2984
Study: 27555133

Group type: EXPERIMENTAL
Intervention: Intravenous 1g paracetamol (Group P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (Group C)
Number of subjects: 60
Study: 24519421

Group type: EXPERIMENTAL
Intervention: 0.5% indomethacin eye drops, four times per day, 16 subjects = 23 eyes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (vehicle of INDOM), 15 subjects = 23 eyes
Number of subjects: 31
Study: 22413021

Group type: EXPERIMENTAL
Intervention: 7 days a week postoperative radiotherapy (p-CAIR)
Number of subjects: 279

Group type: COMPARATOR
Intervention: 5 days a week postoperative radiotherapy (CF)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: High PTEN expression
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: PTEN expression as a predictor
Number of subjects: 279
Study: 20667936

Group type: EXPERIMENTAL
Intervention: Taurine supplementation for 2 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 9
Study: 18980783

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15743151

Group type: EXPERIMENTAL
Intervention: IP (irinotecan [Camptosar]/cisplatin [Platinòl])
Number of subjects: 0

Group type: COMPARATOR
Intervention: EP (etoposide/cisplatin)
Number of subjects: 0
Study: 12611908

Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day ursodeoxycholic acid (UDCA) for 20 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: No bile acid supplement (control)
Number of subjects: 12
Study: 10575906

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E combined with potent inhibitors of platelet aggregation
Number of subjects: 0
Study: 8932266

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tacrolimus and Cyclosporine
Number of subjects: 55
Study: 1914767

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6408995

Group type: EXPERIMENTAL
Intervention: Futraful (FT) alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Futraful (FT) plus cyclophosphamide (Ex)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Futraful (FT) plus Carboquone (CQ)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Overall response rate among the three groups
Number of subjects: 95
Study: 30939189

Group type: EXPERIMENTAL
Intervention: High vitamin premix with 5% RSM
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: High vitamin premix with 10% RSM
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: High vitamin premix
Number of subjects: 674

Group type: COMPARATOR
Intervention: Low vitamin premix
Number of subjects: 674
Study: 28221061

Group type: EXPERIMENTAL
Intervention: PTSD Coach (n = 62)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist condition (n = 58)
Number of subjects: 120
Study: 26644535

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 25147806

Group type: EXPERIMENTAL
Intervention: Renadyl
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study: 23018640

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 19713798

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 17953679

Group type: EXPERIMENTAL
Intervention: 75 mug rhEGF
Number of subjects: 41

Group type: COMPARATOR
Intervention: 25 mug rhEGF
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 15007527

Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreas head resection (Beger technique)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variations of the Beger technique (Frey, Izbicky, Berne modification)
Number of subjects: 0
Study: 11144988

Group type: EXPERIMENTAL
Intervention: Rofecoxib (75 mg once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rofecoxib + digoxin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo + digoxin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 10
Study: 7928182

Group type: EXPERIMENTAL
Intervention: Graded exercise (30 and 90 watts on a cycle ergometer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded exercise with CO2 addition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed external work load (10 minutes at 90 watts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective beta 1‐adrenoceptor blockade (betaxolol) during graded exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonselective beta‐adrenoceptor blockade (levobunolol) during graded exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise with beta‐adrenoceptor blockade
Number of subjects: 0
Study: 2654206

Group type: EXPERIMENTAL
Intervention: MEFAE sodium 720 mg daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DMFAE 240 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: MEFAE sodium up to 240 mg daily
Number of subjects: 36
Study: 968056

Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Tylose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Hyskon)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg 15(S)‐15 methyl PGF2alpha in non‐viscous medium repeated at 12 hours
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium
Number of subjects: 60
Study: 31981370

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) parameters including fractional anisotropy, mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RD)
Number of subjects: 227
Study: 29058097

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (cisplatin 80 mg/m2 for six cycles plus capecitabine 1000 mg/m2 orally bid days 1-14 or 5-fluorouracil 800 mg/m2/day continuous IV infusion days 1-5 every 3 weeks)
Number of subjects: 387
Study: 28352842

Group type: EXPERIMENTAL
Intervention: Self-gripping mesh
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polypropylene mesh with fibrin glue fixation
Number of subjects: 30
Study: 24598306

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (two intravenous doses of 250 mg each)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and placebo
Number of subjects: 7000
Study: 22524991

Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy (MABT)
Number of subjects: 31
Study: 20357378

Group type: EXPERIMENTAL
Intervention: Dietary n‐3 long‐chain polyunsaturated fatty acids (n‐3 LC‐PUFAs)
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Control group (bottom third of dietary n‐3 LC‐PUFAs)
Number of subjects: 1436